Burk et al., identified SHKBP1, ERBB3, CASP8, HLA-A and TGFBR2 as significantly mutated genes and unraveled amplifications in BCAR4, CD274 and PDCD1LG2 in 228 primary cervical cancer, among which multiple genes can be used as therapeutic targets [8]. This evidence concerns the gene HLA-A and cervical cancer.